Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 16/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557360 | 0.95 | WNT3A (0.50) | WNT3A | |
| Trifluoroacetic Acid SCHEMBL18453923 | 0.92 | WNT3A (0.49) | WNT3AAOC3 | |
| Trifluoroacetic Acid SCHEMBL28722159 | 0.88 | WNT3A (0.51) | WNT3A | |
| Trifluoroacetic Acid SCHEMBL29544813 | 0.88 | WNT3A (0.51) | WNT3A | |
| SCHEMBL28937063 | 0.83 | FLT3 (0.47) | GFERMAPTKMT2A | |
| SCHEMBL29389581 | 0.83 | FLT3 (0.47) | GFERMAPTKMT2A | |
| SCHEMBL4069752 | 0.83 | WNT3A (0.58) | WNT3AMEN1MAPTKMT2A | |
| SCHEMBL28394845 | 0.83 | ALDH1A1 (0.52) | MEN1MAPTKMT2A | |
| SCHEMBL18454495 | 0.81 | POLB (0.47) | MEN1MAPTKMT2A | |
| SCHEMBL18453953 | 0.80 | MAPT (0.44) | GFERMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3331880-B3 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-01-11 | — | — | EP | disclosed |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-25 | — | — | US | disclosed |
| CN-114269742-A | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3957637-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Therapeutics Pty Ltd (AU) | 2022-02-23 | — | — | EP | disclosed |
| EP-3331880-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-12-01 | — | — | EP | disclosed |
| CN-113336746-A | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108349964-B | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-3331880-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | University Of South Australia (AU) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017020065-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2017-02-09 | — | — | WO | disclosed |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | WNT3A 2534/4885CASP6 509/4885GFER 4088/4885 |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | WNT3A 1203/4885CASP6 4707/4885GFER 2191/4885 |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | WNT3A 2472/4885CASP6 490/4885GFER 4093/4885 |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK2 | WNT3A 2534/4885CASP6 509/4885GFER 4088/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | WNT3A 2626/4885CASP6 515/4885GFER 4155/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | WNT3A 2638/4885CASP6 303/4885GFER 3979/4885 |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK3 | WNT3A 2638/4885CASP6 303/4885GFER 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.